Navigation Links
Gamida Cell and Cellerix Partner on Feasibility Study
Date:10/21/2009

JERUSALEM and MADRID, October 21 /PRNewswire/ -- Gamida Cell Ltd. and Cellerix, S.A. announced today that the companies are collaborating on a feasibility study to evaluate the added value of combining the proprietary technologies of each.

Gamida Cell is developing a series of technologies to expand, ex vivo, populations of stem/progenitor cells that display increased in vivo homing and engraftment activities. The company's lead product, StemEx(R), comprised of expanded populations of adult stem cells derived from umbilical cord blood (UCB), is used today as an experimental treatment for blood cancers like leukemia and lymphoma. The Company anticipates StemEx(R) will reach the market in 2011.

Cellerix is developing a new generation of cell-based medicines using expanded adult stem cells (eASCs) obtained from adipose tissue. The Company is also very active developing its allogeneic eASCs platform as 2nd generation products through its Cx611 program for high potential markets. eASCs are a natural medicine with the capacity to activate physiological repair mechanisms through interaction with affected tissue. This technology represents a potential revolution in the treatment of some diseases that cannot satisfactorily be cured at present.

"Gamida Cell is enthusiastic about working with Cellerix, a world class company and an industry leader," said Dr. Yael Margolin, president and CEO of Gamida Cell. "Gamida Cell's technologies have demonstrated to improve in vivo functionality of ex-vivo expanded hematopoietic stem cells. This collaboration seeks to evaluate the feasibility of improving clinical efficacy of ex vivo expanded adult stem cells obtained from adipose tissue by means of increasing homing and retention following infusion. The results of this study could lead to an entirely new understanding of the widespread application of our various technologies and expand the number of possibilities for Gamida Cell in terms of product development and partnerships."

"Cellerix has a promising pipeline of cell therapeutics in advanced clinical trials. Existing data shows that Gamida Cell's expansion technologies are very effective in hematopoietic stem cells. Combining the technologies of our companies could lead to developing a new line of cell therapeutics. We are looking forward to seeing the results of this collaboration with an eye on further co-development and commercialization opportunities," said Eduardo Bravo, CEO at Cellerix.

About Cellerix, S.A.

Cellerix is a biopharmaceutical company with a pipeline of late clinical stage cell therapy products (phase II and III) targeting indications that represent a high unmet medical need.

The company has three products undergoing clinical trials: Ontaril(R) (Cx401) for the treatment of complex perianal fistulas, currently in Phase III, first medicine expected to reach the market in 2011, Cx501 a cell therapy product for treating epidermolysis bullosa (EB) currently in Phase II and Cx601 consists of a formulation based on donor cells (allogeneic origin) for treating complex perianal fistulas in Crohn's disease patients now in phase II. Ontaril(R), Cx501 and Cx601 have been designated orphan status by the European Medicines Agency (EMEA). Cellerix has a solid investor base, its ownership structure includes blue chips international VCs and corporate funds from two big pharma companies.

For more information: please visit http://www.cellerix.com.

About Gamida Cell

Gamida Cell Ltd. is a world leader in stem cell expansion technologies and therapeutic products. The company is developing a pipeline of products in stem cell transplantation and in tissue regeneration to effectively treat debilitating and often fatal illnesses such as cancer, hematological and autoimmune diseases. Gamida Cell's therapeutic candidates contain populations of adult stem cells, selected from non-controversial sources such as umbilical cord blood and bone marrow, which are expanded in culture. Gamida Cell was successful in translating these proprietary expansion technologies into robust and validated manufacturing processes under GMP. Gamida Cell's first product, StemEx(R) for blood cancers, is currently being studied in a pivotal registration trial now enrolling patients at leading stem cell transplant centers worldwide (http://www.stemexstudy.com). Gamida Cell's current shareholders include: Elbit Imaging, Biomedical Investment, Israel Healthcare Venture, Teva Pharmaceuticals, Amgen, Denali Ventures and Auriga Ventures.

    For more information, please visit: http://www.gamida-cell.com.

    Press contact for Cellerix:
    Abigail Diaz-Agero
    +34-91-436-1806 or
    adiazagero@comco.es

    Press contact for Gamida Cell:
    Marjie Hadad
    +972-54-536-5220 or
    marjie@gamida-cell.com.

SOURCE Gamida Cell LTD


'/>"/>
SOURCE Gamida Cell LTD
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. CryoLife Expands Distribution of Hemostase MPH(R) to France through Laboratoire Gamida
2. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
3. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
4. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
5. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
6. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
7. GenVault Partnership with Genome Quebec Brings $3.3 Million Sale of Dynamic Archive Product
8. ADVENTRX Pharmaceuticals to Present at the 2007 Thomas Weisel Partners Healthcare Conference
9. Caliper Life Sciences Presentation at Thomas Weisel Partners Healthcare Conference to be Webcast
10. SuperGen to Present at Thomas Weisel Partners Healthcare Conference September 5th
11. NxStage Medical to Present at the Thomas Weisel Partners Healthcare Conference on September 5, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... Feb. 8, 2016  CytRx Corporation (NASDAQ: ... specializing in oncology, today announced that it has ... with Hercules Technology Growth Capital, Inc. and Hercules ... in financing. --> ... million of financing under the loan and security ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... ... Board of Directors. Todorow is the Executive Vice President for Corporate Services and ... Todorow oversees Finance, Accounts Payable, Payroll, Billing Operations, Treasury, Managed Care Contracting, Supply ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... range of loose, bulk foods at various stages of the production process. Despite ... to inspect large bulk products post packaging such as sacks of dry powders. ...
(Date:2/8/2016)... R&D program for the development of future natural products for ... research and development center in Israel ... Stockton has a variety of products adapted ... active in more than 35 counties worldwide. ... flagship product Timorex Gold ® is used to control ...
Breaking Biology Technology:
(Date:2/5/2016)... 5, 2016 http://www.researchandmarkets.com/research/5kvw8m/global_facial ... "Global Facial Recognition Market 2016-2020" ... http://www.researchandmarkets.com/research/5kvw8m/global_facial ) has announced the addition of ... report to their offering. --> ... has announced the addition of the ...
(Date:2/3/2016)... PUNE, India , February 3, 2016 ... to the new market research report "Automated Fingerprint Identification ... (Tenprint Search, Latent Search), Application (Banking & Finance, Government, ... 2020", published by MarketsandMarkets, the market is expected to ... estimated CAGR of 21.0% between 2015 and 2020. The ...
(Date:2/2/2016)... , Feb. 2, 2016  BioMEMS ... are primarily focused on medical screening and ... point-of-care parameters. Wearable devices that facilitate and ... freedom of movement are being bolstered through ... human biomedical signal acquisition coupled with wireless ...
Breaking Biology News(10 mins):